Sra-333
Alzheimer Disease 1
Shanghai Institute of Acupuncture, Moxibustion and MeridianN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Alzheimer Disease 1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aph-1105 Aphios | Phase 2 | CCC |
LECANEMAB Ali Rezai | Early Phase 1 | C |
ADUCANUMAB Ali Rezai | Early Phase 1 | C |
Same molecule, other indications
Sra-333 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →